![Sean Bohen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sean Bohen
Directeur Général chez
OLEMA PHARMACEUTICALS, INC.
Fortune : 3 M $ au 31/07/2026
Profil
Sean P.
Bohen is President, Chief Executive Officer & Director at Olema Pharmaceuticals, Inc. since 2026, Director at Gyroscope Therapeutics Ltd. since 2020, and Non-Executive Director at AltruBio, Inc. since 2019.
Former roles include Non-Executive Director at Gyroscope Therapeutics Holdings Plc from 2020 to 2022, Senior Vice President-Early Development at Genentech, Inc. from 2003 to 2015, Chief Medical Officer & Executive Vice President at AstraZeneca PLC from 2015 to 2019, and Associate at Howard Hughes Medical Institute, Inc. from 2000 to 2003.
Education includes undergraduate studies at the University of Wisconsin and a doctorate from The University of California, San Francisco.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 23/04/2026 | 237 650 ( 0,27 % ) | 3 M $ | 31/07/2026 |
Postes actifs de Sean Bohen
| Sociétés | Poste | Début |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Directeur Général | 01/09/2020 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Directeur/Membre du Conseil | 11/09/2020 |
Altrubio, Inc.
 Altrubio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunomodulators to target diseases of the immune system | Directeur/Membre du Conseil | 01/08/2019 |
Anciens postes connus de Sean Bohen
| Sociétés | Poste | Fin |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Directeur/Membre du Conseil | 17/02/2022 |
| ASTRAZENECA PLC | Directeur Technique/Scientifique/R&D | 14/01/2019 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/07/2015 |
Howard Hughes Medical Institute, Inc.
 Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Corporate Officer/Principal | 01/01/2003 |
Formation de Sean Bohen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
94
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Howard Hughes Medical Institute, Inc.
Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Health Technology |
Altrubio, Inc.
Altrubio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunomodulators to target diseases of the immune system | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Develops clinical-stage gene therapies to treat diseases of eyes | Health Technology |
